赵丽丽¹;冯青青²;赵文飞²;赵文文²;张雪¹;井文君²;魏红梅²

• 1:青岛大学医学部，山东 青岛 266042
• 2:青岛大学附属青岛市中心医院肿瘤综合二科，山东 青岛 266042

摘要(Abstract)：

目的 探讨持续静脉泵入恩度联合免疫治疗和化疗治疗晚期肺鳞癌的近期疗效与安全性。方法 收集一线治疗进展的晚期肺鳞癌患者20例，二线均完成≥ 2个周期恩度持续3 d静脉泵入，联合程序性死亡受体1（programmed death-1，PD-1）抑制剂信迪利单抗及白蛋白紫杉醇治疗。评价患者的临床疗效、生活质量、安全性及治疗前后血管内皮生长因子（vascular endothelial growth factor，VEGF)水平和T淋巴细胞亚群的变化等。结果 患者客观有效率达40.0%，疾病缓解率达90.0%，生活质量总体改善率达70.0%。治疗2个周期后，患者血清VEGF水平低于治疗前，差异具有统计学意义（P<0.05）；患者CD3⁺、CD4⁺和CD4⁺/CD8⁺高于治疗前，CD8⁺低于治疗前，差异均具有统计学意义（均P<0.05）。结论 持续静脉泵入恩度联合信迪利单抗和白蛋白紫杉醇对于晚期肺鳞癌患者安全且有效，可提高患者的生活质量，改善患者免疫力。

关键词(KeyWords)： 肺鳞癌;抗血管生成治疗;免疫治疗;疗效;安全性

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 赵丽丽¹;冯青青²;赵文飞²;赵文文²;张雪¹;井文君²;魏红梅²

DOI: 10.13267/j.cnki.syzlzz.2021.109

参考文献(References)：

• [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
  [2] 吴东平, 徐农. 晚期肺鳞癌治疗现状与前景[J]. 实用肿瘤杂志, 2014, 29(5):408-412.
  [3] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
  [4] Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermo-sifiliogr:Engl Ed, 2021, 112(1):90-92.
  [5] 胡静, 赵明芳. 驱动基因阴性晚期NSCLC一线免疫治疗精彩纷呈:雾里看花[J]. 实用肿瘤杂志, 2020, 35(1):19-24.
  [6] Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135.
  [7] Zhang F, Huang D, Li T, et al. Anti-PD-1 therapy plus chemotherapy and/or bevacizumab as second line or later treatment for patients with advanced non-small cell lung cancer[J]. J Cancer, 2020, 11(3):741-749.
  [8] Luis PA, David V, Ali T, et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous non-small-cell lung cancer:Protocol-specified final analysis of KEYNOTE-407[J]. J Thorac Oncol, 2020, 15(10):1657-1669.
  [9] Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer:A phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(5):709-717.
  [10] Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC:Results from a randomized, double-blind, phase 3 trial (ORIENT-12)[J]. J Thorac Oncol, 2021, 16(9):1501-1511.
  [11] NCCN. NCCN Clinical Practice Guidelines in Oncology:Non-small cell lung cancer (Version 6.2021)[EB/OL]. (2021-09-30)[2021-10-28].https://www.nccn.org/
  [12] 郝捷, 李进, 马军, 等. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2021[M]. 北京:人民卫生出版社, 2021:149.
  [13] Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer:final results of a phase Ⅲ trial[J]. J Clin Oncol, 2012, 30(17):2055-2062.
  [14] Hatem S. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors[J]. Onco Targets Ther, 2016, 10:101-112.
  [15] Johnson DH. Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol, 2004, 22(11):2184-2191.
  [16] 王金万, 孙燕, 刘永煜, 等. 重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J]. 中国肺癌杂志, 2005, 8(4):283-290.
  [17] Huang Y, Kim B, Chan CK, et al. Improving immune-vascular crosstalk for cancer immunotherapy[J]. Nat Rev Immunol, 2018, 18(3):195-203.
  [18] 姜运峰, 董晓鹏, 赵小刚. PD-1单克隆抗体联合血管内皮抑素在Lewis肺癌小鼠的抗肿瘤效应[J]. 山东大学学报:医学版, 2018, 56(09):11-16.
  [19] Wu J, Zhao X, Sun Q, et al. Synergic effect of PD-1 blockade and Endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model[J]. Biomed pharmacother, 2020, 125:109746.
  [20] Li K, Shi M, Qin S. Current status and study progress of recombinant human endostatin in cancer treatment[J]. Oncol Ther, 2018, 6(1):21-43.
  [21] Folkman GAJ. Prediction that broader-spectrum antiangiogenic drugs, lower doses, & continuing doses will improve outcomes[J]. Oncol Tim, 2007, 29(2):38-39.
  [22] Chen Z, Guo W, Cao J, et al. Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients:A phase Ⅰ clinical trial[J]. Cancer Chemother Pharmacol, 2015, 75(3):547-557.
  [23] Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model[J]. Cancer Res, 2001, 61(20):7669-7674.
  [24] Peng Q, Li M, Wang Z, et al. Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin[J]. Thorac Cancer, 2013, 4(3):295-305.
  [25] Jiang XD, Dai P, Jin W, et al. Effect of recombinant human endostatin on radiosensitivity in patients with non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phy, 2011, 83(4):1272-1277.
  [26] 魏红梅, 秦叔逵, 殷晓进, 等. 重组人血管内皮抑素间插联合顺铂对H22小鼠腹水瘤抑制作用的研究[J]. 临床肿瘤学杂志, 2014, 19(2):122-127.
  [27] Shepherd F. Prospective randomized trial of docetaxel versus best supportive care in patients with non-smallcell lung cancer previously treated with platinum-based chemotherapy[J]. J Clin Oncol, 2000, 18(10):2095-2103.
  [28] Fossella FV, Devore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens[J]. J Clin Oncol, 2000, 18(12):2354-2362.
  [29] Yuan C, Ligong N, Ying L, et al. Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first-line chemotherapy in patients with advanced non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(7):1576-1580.
  [30] Li X, Gu G, Soliman F, et al. The evaluation of durative transfusion of Endostar combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Chemotherapy, 2018, 63(4):214-219.
  [31] Wang B, Xu L, Li Q, et al. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC:A systematic review and meta-analysis including non-randomized studies[J]. BMC Cancer, 2020, 20(1):1021.
  [32] Shankar B, Zhang J, Naqash AR, et al.Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer[J]. JAMA Oncol, 2020, 6(12):1952-1956.
  [33] Fukurnura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics:Opportunities and challenges[J]. Nat Rev Clin Oncol, 2018, 15(5):325-340.
  [34] Liu X, Nie W, Xie Q, et al. Endostatin reverses immunosuppression of the tumormicroenvironment in lung carcinoma[J]. Oncol Lett, 2018, 15(2):1874-1880.
  [35] Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape[J]. Mol Cancer, 2019, 18(1):10.
  [36] Ma QY, Huang DY, Zhang HJ, et al. Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer[J]. Int Immunopharmacol, 2016, 41:1-7.